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PMagnetic Resonance Imaging at 1.5-T in
Patients With Implantable Cardioverter-Defibrillators
Claas P. Naehle, MD,* Katharina Strach, MD,* Daniel Thomas, MD,* Carsten Meyer, MD,*
Markus Linhart, MD,† Sascha Bitaraf, MD,‡ Harold Litt, MD, PHD,§ Jörg Otto Schwab, MD,†
Hans Schild, MD,* Torsten Sommer, MD
Bonn, Koblenz, and Neuwied, Germany; and Philadelphia, Pennsylvania
Objectives Our aim was to establish and evaluate a strategy for safe performance of magnetic resonance imaging (MRI) at
1.5-T in patients with implantable cardioverter-defibrillators (ICDs).
Background Expanding indications for ICD placement and MRI becoming the imaging modality of choice for many indications
has created a growing demand for MRI in ICD patients, which is still considered an absolute contraindication.
Methods Non–pacemaker-dependent ICD patients with a clinical need for MRI were included in the study. To minimize
radiofrequency-related lead heating, the specific absorption rate was limited to 2 W/kg. ICDs were repro-
grammed pre-MRI to avoid competitive pacing and potential pro-arrhythmia: 1) the lower rate limit was pro-
grammed as low as reasonably achievable; and 2) arrhythmia detection was programmed on, but therapy deliv-
ery was programmed off. Patients were monitored using electrocardiography and pulse oximetry. All ICDs were
interrogated before and after the MRI examination and after 3 months, including measurement of pacing cap-
ture threshold, lead impedance, battery voltage, and serum troponin I.
Results Eighteen ICD patients underwent a total of 18 MRI examinations at 1.5-T; all examinations were completed
safely. All ICDs could be interrogated and reprogrammed normally post-MRI. No significant changes of pacing
capture threshold, lead impedance, and serum troponin I were observed. Battery voltage decreased significantly
from pre- to post-MRI. In 2 MRI examinations, oversensing of radiofrequency noise as ventricular fibrillation oc-
curred. However, no attempt at therapy delivery was made.
Conclusions MRI of non–pacemaker-dependent ICD patients can be performed with an acceptable risk/benefit ratio under
controlled conditions by taking both MRI- and pacemaker-related precautions. (Implantable Cardioverter Defibril-
lators and Magnetic Resonance Imaging of the Heart at 1.5-Tesla; NCT00356239) (J Am Coll Cardiol 2009;54:
549–55) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.04.050a
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secent studies have suggested that magnetic resonance
maging (MRI) at 1.5-T can be performed safely in patients
ith implanted cardiac pacemakers (PMs) in carefully
elected circumstances. In comparison with PMs, safety
ssues in imaging of patients with implantable cardioverter-
efibrillators (ICDs) are more complex. Although MRI was
erformed without complications previously (1–5), the pres-
nce of an ICD is still considered an off-label procedure and
rom the Departments of *Radiology and †Cardiology, University of Bonn, Bonn,
ermany; ‡Department of Internal Medicine–Cardiology, Katholisches Klinikum
oblenz–Marienhof, Koblenz, Germany; §Department of Radiology, University of
ennsylvania School of Medicine, Philadelphia, Pennsylvania; and the Department
f Radiology, German Red Cross Hospital, Neuwied, Germany. Dr. Litt has received
esearch grants from Siemens Medical Solutions (Malvern, Pennsylvania). Dr.
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St. Paul, Minnesota). Dr. Sommer is a consultant to Medtronic (Minneapolis,
innesota).a
Manuscript received January 22, 2009; revised manuscript received March 9, 2009,
ccepted April 15, 2009.strong relative contraindication for MRI (6,7), and most
atients with ICDs are denied for MRI despite its unpar-
lleled capabilities for diagnosis and planning of treatment.
he purpose of our study was to establish a strategy for safe
erformance of MRI at 1.5-T in ICD patients and to
valuate the safety and feasibility of this strategy.
ethods
tudy subjects. Eighteen patients with an ICD and an
rgent clinical indication for MRI were enrolled prospec-
ively. Inclusion and exclusion criteria are shown in Table 1.
See page 556
he study design is summarized in Table 2. The institu-
ional review board of the relevant institution approved the
tudy protocol. Signed informed consent was obtained from
ll subjects.
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All MRI examinations were per-
formed on an actively shielded
1.5-T MRI scanner (Intera,
1.5-T, Philips, Best, the Nether-
lands) (gradient system: maximum
amplitude 33 mT/m, maximum
slew rate 80 mT/m/s, minimum
rise time 0.41 ms). All clinically
relevant MRI sequences necessary
for diagnosis were performed. To
minimize the risk of radiofre-
quency (RF)-related lead heating,
the specific absorption rate (SAR)
was limited to 2 W/kg.
re/post-MRI ICD evaluation and reprogramming. All
CDs were interrogated before and immediately after MRI
Fig. 1). The following parameter changes pre/post MRI were
efined to be clinically significant and MRI-related: 1) pacing
apture threshold increase 1.0 V at 0.4 ms pulse duration;
) increase or decrease of pacing lead impedance to 2,000 
r 200 ; 3) increase or decrease of high-voltage lead
mpedance to 80  or 10  (8); and 4) ability to
nterrogate the device. If any MRI-related parameter
hanges were noted, a chest X-ray and an ICD test were
erformed. Before MRI, all ICDs were reprogrammed to
inimize the risk of interference with the MRI system (Fig.
). Serum troponin I was measured within 1 h before and 12
o 24 h after MRI to detect myocardial injury. Each patient
as asked to immediately inform the investigator of any
orquing, movement, or heating sensation about the ICD
ocket, and other unusual sensations during MRI.
nclusion and Exclusion Criteria for Patients With ICDsTable 1 Inclusion and Exclusion Criteria for Patients With ICDs
Inclusion criteria
Urgent need for an MRI examination
No restrictions on ICD manufacturer, model of the device or leads, or scanned
region
Presence of an ICD system
Stable physical parameters
Battery estimated remaining lifetime 6 months
Pacing lead impedances 200 to 2,000 
Shock lead impedance 10 to 80 
Stable pacing parameters
Pacing capture threshold 2.5 V at a pulse duration of 0.4 ms
Sensing 5 mV
Minimum 3 months since ICD and lead implantation
Exclusion criteria
Unstable angina
Myocardial infarction within the previous 3 months
Cardiothoracic surgery within the previous 3 months
Pacemaker dependency (defined as an intrinsic heart rate 50 beats/min)
Presence of MRI incompatible bioimplants or other MRI incompatible
materials
Presence of abandoned leads
Abbreviations
and Acronyms
ATP  antitachycardia
pacing
DC  direct current
ICD  implantable
cardioverter-defibrillator
MRI  magnetic resonance
imaging
PM  pacemaker
RF  radiofrequency
SAR  specific absorption
ratetCD  implantable cardioverter-defibrillator; MRI  magnetic resonance imaging.tatistical analysis. Troponin I levels were compared using
he Student t test; all other parameters were compared using
he Wilcoxon signed rank test. The level of significance was
et to a value of 0.05.
esults
he study group consisted of 18 consecutive patients (mean
ge 61.8 years) on which a total of 18 MRI examinations
ere performed. ICD models, ICD leads, and scanned
RI regions are given in Table 3. The 3-month follow-up
nterrogation was performed after 18 of 18 (100%) exami-
ations (mean follow-up interval 92.8 days, range 73 to 115
ays).
linical events during the MRI examinations. All MRI
xaminations (100%) were completed safely. None of the
atients reported any torque or heating sensations, or other
nusual symptoms during MRI. No unexpected changes in
eart rate or rhythm, indicating inhibition of ICD output,
hock delivery, or sustained atrial or ventricular arrhythmias
ere observed during any MRI examination (0 of 18, 0%).
CD reprogramming. In 18 of 18 (100%) patients, the
nderlying intrinsic heart rate was 50 beats/min, and the
CDs were reprogrammed to an inhibited pacing mode with
ubthreshold pacing, or pacing was programmed “off” (Ta-
le 3). In 17 of 18 patients (94.4%), the ICD was pro-
rammed to a monitor-only mode (arrhythmia detection
n, therapies delivery off). In 1 patient (1 of 18, 5.6%), both
rrhythmia detection and therapy delivery were pro-
rammed “off,” as a monitor-only mode was not available in
he specific device (Atlas, St. Jude Medical, St. Paul,
innesota). In no patient (18 of 18, 100%) did an electrical
eset occur during MRI.
CD status. In all devices (18 of 18, 100%), the capability
o interrogate the ICD device using telemetry remained
reserved. No clinically significant change of pacing capture
tudy Design for ICDs in the MRI EnvironmentTable 2 Study Design for ICDs in the MRI Environment
Pre-MRI Post-MRI 3-Month Follow-Up
Assessment of inclusion
and exclusion criteria
X — —
Medical history X — X
Written informed consent X — —
Physical examination X X X
Complete pacemaker
interrogation and
reprogramming
X X X
X-ray if pacing threshold
change 1 V at 0.4 ms
pulse duration
— X X
Assessment of serum
troponin I level
X X —
ICD test if clinically
significant parameter
changes
— X X
bbreviations as in Table 1.hreshold or lead impedance was observed (Table 4). Mean
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August 4, 2009:549–55 MRI in ICD Patientsercentage change in lead impedance from pre-MRI to
ost-MRI was 1.86  5.10 , and from pre-MRI to
ollow-up 0.57  4.43 . Mean battery voltage was 3.86 
.48 V pre-MRI, 3.83  1.48 V post-MRI, and 3.90 
.52 V at follow-up (Table 4). The decrease in battery
oltage from pre- to post-MRI was statistically significant
p  0.0420). A full recovery of battery voltage at follow-up
as observed after 4 of 16 (25.0%) MRI examinations.
ean charge time pre-MRI, post-MRI, and at follow-up
re given in Table 4. There was a significant decrease in the
harge time from 11.15  4.86 s pre-MRI to 9.48  4.28 s
ost-MRI (p  0.0034).
F oversensing/therapy delivery. For 1 device (St. Jude
edical, Atlas) assessment of RF oversensing was not
ossible, as both tachyarrhythmia detection and therapy had
o be deactivated in this device. For the remaining 17
agnetic resonance (MR) examinations, RF oversensing as
entricular arrhythmia occurred in 2 of 17 examinations
11.8%). As both devices (Guidant CPI Ventak Prizm DR
nd Guidant CPI Ventak Prizm 2 VR, Guidant [now
oston Scientific], Indianapolis, Indiana) had been repro-
rammed to a detection-only mode before MRI according
o the study protocol, no attempt at therapy delivery (0 of 2,
%) was made.
roponin I. Eighteen blood samples were analyzed, and
o increase of troponin I level above the upper normal limit
f 0.1 ng/ml was observed after any of the examinations (0
f 18, 0%) (Table 4).
iscussion
CDs primarily monitor heart rate and rhythm for malig-
ant tachycardia and deliver antitachycardia pacing (ATP)
Figure 1 ICD Interrogation and Reprogramming Pre-MRI, Post-M
ICD  implantable cardioverter-defibrillator; MRI  magnetic resonance imaging; 0r direct current (DC) shock delivery to restore normal (eart rate and rhythm. Therefore, ICDs differ from PMs to
great extent: 1) increased ferromagnetic mass (larger
attery, presence of transformer and capacitor), increasing
agnetic translation forces and torque; 2) longer leads with
larger diameter with shock coils; 3) advanced integrated
ircuitry allowing for analysis of both heart rate and rhythm;
nd 4) additional hardware (e.g., transformer, integrated
ircuitry, capacitor) and software to allow for therapy
elivery with risk of damage to hardware components and
nappropriate therapy delivery due to oversensing of elec-
romagnetic noise by the MRI system.
F-related heating. RF-related heating for ICD leads has
een shown to reach up to 7.2°C in vitro (9), which is
enerally considered negligible in terms of safety and
iologic effects (10). However, RF-induced heating is dif-
cult to simulate in vitro given the numerous possible
ombinations of devices and leads and the infinite number
f possible different geometric configurations of the leads
ithin the chest, which are known to alter the amount of
eating considerably (11). Therefore, to be conservative, we
imited the SAR to 2.0 W/kg in our study to minimize the
isk of RF-related lead heating. Maximum RF-induced
eating occurs at the electrode-tissue boundary and may
ead to deterioration of pacing thresholds (9,12). The
nding that lead impedances and pacing thresholds re-
ained unchanged in our study and that no increase in
roponin I was measured after MRI confirm that no
linically relevant thermal injury occurred at the ICD lead
ips (Fig. 2). These findings are concordant with previous
tudies and several case reports, which also did not find any
vidence for thermal injury after MRI in ICD patients
and at Follow-Up
sense-only mode.RI,
X0 1–5,9).
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MRI in ICD Patients August 4, 2009:549–55atient, MRI Examination, and ICD System Characteristics Including Programmed Parameters During MRITable 3 Patient, MRI Examination, and ICD System Characteristics Including Programmed Parameters During MRI
MRI
Examination
Patient
Age (yrs)
Scanned
Region
ICD Manufacturer
and Model* Leads Pacing Mode
Antitachycardia
Mode
RF
Oversensing
Battery Voltage
at Follow-Up
1 69.3 Heart Medtronic GEM III A: —
V: Medtronic 6947 (Sprint Quattro
Secure)
Add: —
VVI/sth Detection enabled,
therapy disabled
No No recovery
2 43.9 Brain Biotronik Lexos VR A: —
V: Medtronic 6943 (Sprint)
Add: —
Off Detection enabled,
therapy disabled
No Partial recovery
3 76.9 Cervial spine Ela Medical
Defender
A: Medtronic 5068 (CapsureFix)
V: Medtronic 6943 (Sprint)
Add: —
VVI/sth Detection enabled,
therapy disabled
No No data
4 84.2 MRA legs Ela Medical Alto A: unknown
V: Ela 4041 (AngePass)
Add: —
VVI/sth Detection enabled,
therapy disabled
No No data
5 49.3 Heart Guidant CPI Vitality 2 A: —
V: Medtronic 6943 (Sprint)
Add: —
Off Detection enabled,
therapy disabled
No No recovery
6 72.6 Abdomen Medtronic GEM II VR A: —
V: Medtronic 6942 (Sprint)
Add: —
VVI/sth Detection enabled,
therapy disabled
No Partial recovery
7 46.9 Entire spine Medtronic Jewel
7221 Cx
A: —
V: Medtronic 6936 (Transvene RV)
Add: —
0V0 Detection enabled,
therapy disabled
No Partial recovery
8 64.4 Thoracic and
lumbar
spine
Medtronic Maximo
VR 7232
A: —
V: Medtronic 6947 (Sprint Quattro
Secure)
Add: —
0V0 Detection enabled,
therapy disabled
No No recovery
9 70.9 Brain Guidant CPI Ventak
PRIZM 2 VR
A: —
V: Guidant 0155 (Endotak
Endurance EZ)
Add: —
Off Detection enabled,
therapy disabled
Yes Partial recovery
10 60.8 Brain Medtronic GEM II VR
7229 Cx
A: —
V: Medtronic 6943 Sprint
Add: Medtronic 6996 (SQ)
VVI/sth Detection enabled,
therapy disabled
No Partial recovery
11 51.9 Lumbar
spine
St. Jude Medical
Atlas VR
A: —
V: St. Jude Medical 1582 (Riata)
Add: —
Off Off (detection disabled,
therapy disabled)
No Complete
recovery
12 78.2 Thoracic and
lumbar
spine
Guidant CPI Vitality 2 A: —
V: Guidant 0176 (Endotak
Reliance G)
Add: —
Off Detection enabled,
therapy disabled
No Partial recovery
13 54.1 Heart Medtronic GEM III A: Ela BSC45 (Stela)
V: Medtronic 6943 Sprint
Add: —
VVI/sth Detection enabled,
therapy disabled
No Partial recovery
14 38.7 Heart Guidant CPI Ventak
PRIZM DR
A: Medtronic 4269 (Sweet Tip)
V: Guidant 0125 (Endotak DSP)
Add: —
Off Detection enabled,
therapy disabled
Yes Complete
recovery
15 54.5 Heart Medtronic GEM III A: Ela BSC45 (Stela)
V: Medtronic 6943 Sprint
Add: —
VVI/sth Detection enabled,
therapy disabled
No Partial recovery
16 66.5 Brain Biotronik Lexos VR-T A: —
V: Biotronik Kentrox RV 75
Add: —
Off Detection enabled,
therapy disabled
No Complete
recovery
17 67.0 Brain Biotronik Lexos VR-T A: —
V: Biotronik Kentrox RV 75
Add: —
Off Detection enabled,
therapy disabled
No Complete
recovery
18 73.0 Knee Medtronic Insync III
Marquis
A: Medtronic 4076
V: Medtronic 6943 Sprint
Add: Medtronic 4194 (coronary
sinus)
0D0 Detection enabled,
therapy disabled
No Partial recovery
omplete recovery recovery of battery voltage at follow-up compared with pre-MRI baseline value; No recovery decrease of battery voltage0.05 V at follow-up compared with pre-MRI baseline value;
artial recovery decrease of battery voltage0.01 V and0.05 V at follow-up compared with pre-MRI baseline value. *Manufacturers: Biotronik, Berlin, Germany; Ela Medical (now Sorin Group), Munich,
ermany; see text for details of the other manufacturers.
A  atrial; Add  additional lead(s); MRA magnetic resonance angiography; RF  radiofrequency; sth  subthreshold; V  ventricular; 0D0/0V0  sense-only mode; other abbreviations as in Table 1.
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August 4, 2009:549–55 MRI in ICD PatientsRI interference with ICD functionality. OVERSENSING
F RF FIELDS. In our study, oversensing of RF noise as
entricular fibrillation was observed in 2 of 17 MRI exam-
nations (Fig. 3). Due to deactivation of therapy delivery
efore MRI, no attempt at therapy delivery was recorded
Fig. 4). To date, it seems highly unlikely that ICDs can
erform DC shock delivery within the MR environment.
or DC shock delivery (20 to 700 V), the battery voltage (3
o 6 V) has to be transformed to charge the capacitor.
owever, the static magnetic field saturates the transformer,
esulting in a short circuit with ineffective voltage transfor-
ation and the inability to charge the capacitor (13).
owever, other important safety issues are associated with
versensing of MR noise by ICDs: 1) unintended attempts
o charge the capacitor can cause battery depletion; 2) some
CD devices permanently inactivate therapy delivery after a
ertain number of unsuccessful attempts to charge the
apacitor, which might necessitate device replacement;
) inappropriate ATP due to RF oversensing could induce
entricular arrhythmia due to asynchronous stimulation;
nd 4) a short circuit within the electronic circuits may
ermanently damage the ICD (14,15), necessitating device
eplacement. Therefore, to minimize the risk of attempted
Figure 2 Midventricular Short-Axis MRIs of the Heart in a Patie
(Left) Steady-state free precession sequence, demonstrating wall thinning of the s
myocardial scar in the septum (black arrow). Note the susceptibility artifacts in th
in the pectoral region due to the implantable cardioverter-defibrillator (*). MI  my
ICD Data Before and After MRI and at Follow-UpTable 4 ICD Data Before and After MRI and
Parameter Pre-MRI Post
PCT (V) 1.01 0.83 1.00
Lead impedance () 594.0 151.7 581.0
HV impedance () 39.4 18.4 39.6
Battery voltage (V) 3.86 1.48 3.83
Charge time (s) 11.2 4.9 9.5
Troponin (ng/ml) 0.01 0.01 0.01
HV  high-voltage; PCT  pacing capture threshold; other abbreviationadequate therapy delivery due to RF oversensing, therapy
elivery (ATP and DC shock) was completely deactivated
efore MRI.
EED SWITCH. In magnetic fields200 mT, the reed switch
emains open in 50% of spatial orientations and is closed
nly in 50% of spatial orientations (13) with consecutive
eactivation of therapy delivery. Reactivation of therapy
elivery after opening of the reed switch is manufacturer
ependent (16). Therefore, ICD reprogramming before
RI with deactivation of therapy delivery and ICD inter-
ogation after MRI is mandatory to ensure appropriate
evice programming with reactivated arrhythmia detection
nd therapy delivery.
APACITOR TESTING. The time needed to fully charge the
apacitor is an important indicator for effective therapy deliv-
ry, because a prolonged charge time can lead to ineffective
herapy delivery (17,18). In our study, the charge time de-
reased significantly from pre- to post-MRI measurement. We
heorize that this decrease in charge time is not MRI related,
ut rather due to the charge test performed before MRI,
eaving the capacitor already reformatted for post-MRI testing
nd leading to a decreased charge time by itself.
ith a Chronic MI
wall. (Right) Three-dimensional inversion recovery viability imaging, indicating the
t ventricle due to the implantable cardioverter-defibrillator lead (open arrows) and
ial infarction; MRI  magnetic resonance imaging.
8 ICD Patientsllow-Up in 18 ICD Patients
Follow-Up p Value (Pre-/Post-MRI)
1.03 0.80 0.5000 (n 23)
4 595.6 153.4 0.1297 (n 23)
37.6 17.6 0.8125 (n 14)
3.90 1.52 0.0420 (n 16)
10.6 4.6 0.0034 (n 12)
— 0.2596 (n 18)
Table 1.nt W
eptal
e righ
ocardin 1at Fo
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MRI in ICD Patients August 4, 2009:549–55ATTERY VOLTAGE. In the present study on ICDs in the
RI environment, a slight, but significant (p  0.0420)
ecrease in battery voltage (3.86  1.48 V vs. 3.83  1.51
) was demonstrated from pre- to post-MRI. Several
echanisms can lead to battery depletion: 1) charging of
he capacitor due to oversensing of RF noise; 2) sustained
ctivation of telemetry due to closure of the reed switch;
nd 3) electrical short circuits within the ICD. In the
resent studies, no attempts to charge the capacitor were
oted, and it is unknown to what extent the activation of
elemetry and possible short circuits contributed to the
rop in battery voltage. Therefore, it is mandatory to
erform a complete device interrogation immediately
fter MRI to assess if: 1) battery depletion; 2) an
lectrical reset with subsequent restoration of factory
Figure 3 EGM Recorded at the Beginning of an MRI Sequence
Traces shown from top to bottom are: ventricular electrogram (EGM), shock coil EG
tricular signals with correct classification as ventricular sensing (VS) (*). After the
of radiofrequency noise in the ventricular EGM occurs with classification as ventric
nel). MRI  magnetic resonance imaging.
Figure 4 EGM With Sustained Oversensing of RF Noise by an IC
Traces shown from top to bottom are ventricular electrogram (EGM), shock coil EG
classified as ventricular fibrillation (VF) (arrows) by the arrhythmia detection algori
was reprogrammed to a monitor only mode (*) before MRI. Abbreviations as in Figefault settings; or 3) permanent inactivation of therapy
elivery due to multiple attempts to charge the capacitor
as occurred.
Contrary to previous PM studies, in which a complete
ecovery was noted in 66.1% of the MRI examinations (12), in
his study a complete recovery of battery voltage was noted in
nly 4 of 16 examinations (25.0%). In addition, after 3 of 16
18.8%) examinations in our study, a persisting decrease in
attery voltage0.05 V was observed. This finding may be of
ajor importance for several reasons: 1) a decrease in battery
oltage can lead to a prolonged charge time, which, in turn,
elays therapy delivery for malignant ventricular tachycardia
nd decreases the likelihood of successful rhythm conversion
19); and 2) a decrease in battery voltage may necessitate early
evice replacement.
d marker channel. Initial ventricular EGM shows regular sensing of intrinsic ven-
f t scan sequence with radiofrequency pulses for image acquisition, oversensing
rillation (VF) (arrows) by the arrhythmia detection algorithm (see marker chan-
uring MRI
d marker channel. Radiofrequency (RF) noise (ventricular channel, top trace) is
ee marker channel). However, no therapy delivery was attempted as the deviceM, an
start o
ular fibD D
M, an
thm (s
ure 1.
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August 4, 2009:549–55 MRI in ICD Patientsonclusions
he results of the present study demonstrate that MR exam-
nations in patients with ICDs may be performed safely under
ontrolled conditions and using several precautionary mea-
ures, including: 1) minimizing the risk of RF-related lead
eating and myocardial thermal injury limitation by limiting
he SAR to 2.0 W/kg; 2) reprogramming the ICD with
eactivation of therapy delivery; 3) reprogramming the
CD to VVI pacing with the lowest possible lower rate
imit; 4) continuous monitoring of electrocardiogram and
ulse oximetry; 5) presence of an electrophysiologist and
ull resuscitation facilities at the MRI site; 6) ICD interro-
ation immediately after MRI to exclude clinically relevant
hanges in the technical and functional ICD parameters;
nd 7) exclusion of PM-dependent ICD patients. Utilizing
hese ICD, MRI, and monitoring-related safety precau-
ions, we did not observe any damage to the ICD systems,
ny unexpected changes in heart rate or rhythm, any
ttempted therapy delivery, or any evidence for RF-related
yocardial thermal damage during or after MRI. There-
ore, we believe that in selected patients with an urgent
linical need to undergo MRI in the absence of an alterna-
ive imaging modality, MRI in patients with ICDs at 1.5-T
arries an acceptable benefit/risk ratio.
eprint requests and correspondence: Dr. Claas P. Naehle,
epartment of Radiology, University of Bonn, Sigmund-Freud-
tr. 25, 53105 Bonn, Germany. E-mail: cp@naehle.net.
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